Economic news

Biogen confirms $5 billion shares repurchase

Biogen announces a $5 billion buyback in shares a few days after it reports that it is suspending clinical trials of a drug that is expected to be a breakthrough in the treatment of Alzheimer's disease.

biogen repurchases shares 2503Photo: Reuters

Biogen Inc said it would buy back its shares worth $5 billion on Monday,  after a massive drop in their value followed last week as a result of the discontinuation of drug research at its final testing stage.

The American multinational biotechnology company lost more than $18 billion of its value last week after Biogen and Eisai Co Ltd, a Japanese partner, completed their tests in the run up to the third, final, experimental study of the effects of adukanumab on a disease like Alzheimer.

Shares of Biogen lost 32.4 percent of their value since the announcement of the termination of testing on Thursday, although on Monday the company's securities showed a positive trend, showing an increase of 1.73 percent at 13.43 GMT.

Under the program to repurchase its own shares for 2019, there is still a sum of $1.7 billion, approved by the board of directors in August last year, according to company’s post.


To leave a comment you must or Join us


More news


Back to economic news list

By visiting our website and services, you agree to the conditions of use of cookies. Learn more
I agree